BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Home » Blogs » BioWorld Perspectives » Unless it’s Affordable, Curing Cancer is Just a Dream

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Drug resistance / Cancer

Unless it’s Affordable, Curing Cancer is Just a Dream

Aug. 30, 2011
By Mari Serebrov

Although they’re the stuff of science, statistics too often lack the power to move us. After all, they’re just numbers. So when companies like Dendreon Corp. and Seattle Genetics Inc. price their cancer treatments at nearly $100,000 or more, we may arch our eyebrows, but we don’t really think about the impact those prices will have on the individual faces and names behind the numbers. Instead, we wonder, as reported in BioWorld Today, why more patients don’t take advantage of promising drugs like Dendreon’s Provenge.

Unlike statistics, faces and names have stories that can bring us to tears, that make us want to shout at the unfairness of life, that inspire us to reach beyond ourselves to make the world a little bit better for someone else. My niece Jaymi is one of those names.

She was diagnosed with Hodgkin’s when she was 15. After a cocktail of chemo and radiation, full-body radiation and an unsuccessful bone marrow transplant, her doctors basically told her to enjoy what little life she had left. She took them at their word. She went to college. She married her high school sweetheart. And, against all odds, she gave birth to a beautiful, healthy baby girl (pictured here with Jaymi).

At 23, Jaymi is a senior in college, majoring in technical writing and communications. Next year, she plans to start her MBA. Outside of school, she enjoys every minute she has with her 2-year-old daughter and her husband, who also is a college student. But her life is shadowed by the cancer that continues to spread throughout her body.

Jaymi doesn’t need hope. She sees that every time she looks in her daughter’s eyes. What Jaymi needs is a cure. But she needs one that is affordable.

Because she’s a married college student with cancer, Jaymi doesn’t have private insurance. And although she’s eligible for disability and Medicaid, she’s still waiting for the forms to enroll in the government programs. She’s also been warned by Medicare staff that pursuing full-on cancer treatment may not be feasible in light of budget cuts.

Years before Jaymi was born, scientists dreamed of finding a cure for cancer. Those dreams are coming true. But for people like Jaymi, the cure is still just a dream they can’t afford.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 29, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing